Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00360425 · ClinicalTrials.gov registry record · Phase 1

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

A Phase 1 study of Anemia, sponsored by AMAG Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
174
Enrollment target
1
Study location

NCT00360425 is a Phase 1 study of Anemia that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 174 participants, below the 425-participant average among 72 other Anemia trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00360425, a Phase 1 study of Anemia, has completed, sponsored by AMAG Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
174 participants
Enrollment target
1
Study location

Study Summary

This study will define the effects of ferumoxytol on electrocardiogram (ECG) data as well as evaluate pharmacokinetics

Conditions Studied

Anemia

Interventions

  • DRUG placebo
  • DRUG ferumoxytol
  • DRUG moxifloxacin

Study Locations (1)

Maryland

  • - Baltimore

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2006-05
Est. Completion 2006-08
Phase Phase 1

Sponsor

AMAG Pharmaceuticals

23 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00360425

The ClinicalTrials.gov registry entry for NCT00360425 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 425-participant average among 72 other Anemia trials with a reported enrollment target (59% lower). The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00360425 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00360425 about?

NCT00360425 is a clinical study titled "A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women". This study will define the effects of ferumoxytol on electrocardiogram (ECG) data as well as evaluate pharmacokinetics

What is the current status of trial NCT00360425?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2006-05. Estimated completion is 2006-08.

What conditions does trial NCT00360425 study?

This clinical trial studies the following conditions: Anemia.

What interventions are being tested in trial NCT00360425?

The interventions under investigation include: placebo (DRUG), ferumoxytol (DRUG), moxifloxacin (DRUG).

Who is sponsoring clinical trial NCT00360425?

This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00360425 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anemia

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.